Targeting angiogenesis in non-small cell lung cancer: Agents in practice and clinical development

European journal of Clinical and Medical Oncology

Volumn 2, Issue 1, 2010, Pages

  Barzi, Afsaneh ^a   Pennell, Nathan A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Clinical trials; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CELGENE; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMCLONE; IRINOTECAN; IXABEPILONE; MOTESANIB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VATALANIB; XL 647;

ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DYSPNEA; ENDOTHELIUM CELL; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PROTEINURIA; QT PROLONGATION; RASH; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR CELL; TUMOR GROWTH; VASOCONSTRICTION; VOICE CHANGE; VOMITING;

EID: 77956276361     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
4. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8:72-9.
5. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591-7.
6. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988;240:177-84.
7. Adam JA, Maggelakis SA. Diffusion regulated growth characteristics of a spherical prevascular carcinoma. Bull Math Biol. 1990;52:549-82.
8. Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136:261-76.
9. Gimbrone MA, Jr Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974;52:413-27.
10. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991;51:6180-4.
11. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64.
13. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991;66:1095-104.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
15. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-5.
16. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-8.
17. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995; 14:263-77.
18. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A. 2005;102:2934-9.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
20. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg. 1994;57:1534-9.
21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
22. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246:1306-9.
23. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40.
24. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-91.
25. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:650-6.
26. Novello S, Falcone A, Crino L, et al. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer. 2009.
27. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117-24.
28. Rizvi NA, et al. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. In: ASCO; 2007.
29. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60:5565-70.
30. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
31. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
32. Dallas NA, Fan F, Gray MJ, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev. 2007;26:433-41.
33. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129-35.
34. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-77.
35. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
36. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9.
37. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-50.
38. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-6.
39. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
40. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-91.
41. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-50.
42. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27: 1227-34.
43. Manegold Cea. BO17704 (AVAIL): A Phase III Randomised Study of First- Line Bevacizumab Combined With Cisplatin/Gemcitabine (CG) in Patients With Advanced or Recurrent Non-Squamous, Non-Small Cell Lung Cancer (NSCLC). In: ESMO; 2008.
44. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009;15:2594-601.
45. Hainsworth J, Lin, M. A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized, Clinical Trial to Evaluate the Efficacy of Bevacizumab (AvastinH) in Combination with Erlotinib (TarcevaH) Compared with Erlotinib Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard First Line Chemotherapy (BETA). In: J Thoracic Oncl; 2008.
46. Miller VA, O'Connor, P et al. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2009;27:No 18S June 20 Supplement (LBA8002).
47. Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non- Small Cell Lung Cancer National Cancer Institute. (Accessed Oct, 12, 2009, at http://www.cancer.gov/clinicaltrials/search.)
48. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res. 2007;13:s4623-7.
49. Massarelli E, Miller, V. A. et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol. Vol 25, No. 18S (June 20 Supplement), 2007: 7627.
50. A Study of Aflibercept Versus Placebo in PatientsWith Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer National Cancer Institute. (Accessed Oct, 12, 2009, at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid5570879&protocolsearchid56866381&version5healthprofessional.)
51. Blumenschein GR, Jr., Gatzemeier U, Fossella F, et alPhase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4274-80.
52. Schiller JH, Flaherty, K. T. Sorafenib combined with carboplatin/ paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol. 2006;24 No 18S (June 20 Supplement), 2006: 7194.
53. Schiller JH, Lee, J. W. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol. 2008;26 No 15S (May 20 Supplement), 2008: 8014.
54. Hanna NH, Pawel, J. V. et al. Carboplatin/paclitaxel With/without Sorafenib In Chemonaive Patients With Stage IIIB-IV Non-small Cell Lung Cancer (nsclc): Interim Analysis (ia) Results From a Randomized Phase III Trial (escape). Journal of Thoracic Oncology. 2008;3(Suppl 4), S268.
55. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009;101:1543-8.
56. Genentech warns against use of Avastin in combination with sunitinib MD Consult. (Accessed 2009, at http://www.mdconsult.com/das/news/body/167624491-2/drug/0/197402/1.html?pos5fdasafety.)
57. CALGB. Randomized, phase III, double-blind placebo-controlled trial of sunitinib (NSC #736511, IND #74019) as maintenance therapy in nonprogressing patients following an initial four cycles of platinumbased combination chemotherapy in advanced, stage IIIB/IV nonsmall cell lung cancer / 60702 Pharmacogenetic Studies in CALGB 30607. Quarterly Newsletter of The Cancer and Leukemia Group B 2009.
58. Natale Rea. Vandetanib versus erlotinib in patients with advanced nonsmall- cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). In: ASCO; 2009.
59. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14:378-90.
60. Herbst RSea. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). In: ASCO; 2009.
61. De Boer Rea. Vandetanib plus pemetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL). In: 13th World Conference on Lung Cancer; 2009.
62. AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC. 2009. (Accessed 11/6, 2009, at http://www.astrazeneca.com/media/latest-press-releases/zactima-adv-NSCLC?itemId57317146.)
63. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2008;26:1871-8.
64. Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2009;45:782-8.
65. Laurie Sea. Overall survival results of NCIC Clinical Trials Group BR.24: a randomized, double-blind trial of carboplatin + paclitaxel with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer. In: 13th World Conference on Lung Cancer; 2009.
66. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:2369-76.
67. Blumenschein G, Jr., Sandler, A, O'Rourke, T et al. Safety and pharmacokinetics of AMG 706, panitumumab, and carboplatin/paclitaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC). In: ASCO; 2006: Journal of Clinical Oncology; 2006. p 7119.
68. Crawford J, Burris, H, Stephenson, J et al. Safety and pharmacokinetics of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients with advanced cancer. In: ASCO; 2007: J of Clin Onco; 2007.
69. MONET1-Motesanib NSCLC Efficacy and Tolerability Study National Cancer Institute. (Accessed 2009, at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid5544064&version5HealthProfessional&protocolsearchid56919201.)
70. Phase 3 Trial of Motesanib in Non-Small-Cell Lung Cancer Suspended. In: Medscape; 2008.
71. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23:5474-83.
72. Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009;27:3836-41.
73. Altorki Nea. Phase II Study of Pazopanib Given Preoperatively in Stage I-II Non-Small Cell Lung Cancer (NSCLC): A Proof-of-Concept Study. In: ESMO; 2008.
74. Gauler TC, Besse, B, Meric, J. B., et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients with stage IIIB/IV non-small cell lung cancer. In: ASCO; 2007: J Clin Oncol; 2007.
75. Gelati M, Corsini E, Frigerio S, et al. Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol. 2003;64:193-201.
76. Du GJ, Lin HH, Xu QT, Wang MW. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005;43:112-9.
77. Miller AA, Case D, Atkins JN, Giguere JK, Bearden JD. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced nonsmall cell lung cancer. J Thorac Oncol. 2006;1:832-6.
78. Lee SM, Rudd R, Woll PJ, et al. Randomized Double-Blind Placebo- Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2009; 27:5248-54.
79. Rizvi NA, Kris MG, Miller VA, et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Journal of Clinical Oncology. 2008;26:abstr 8053.
80. Miller VA, Wakelee, H. A., Lara, P.N., et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol. 2008;26 2008 (May 20 suppl; abstr 8028).
81. Von Pawel Jea. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced NSCLC. In: ASCO; 2007.
82. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-27.
83. Hutson Tea. Predictive and Prognostic Factors in Phase II Renal Cell Carcinoma Trial With Pazopanib, a Multi-Kinase Angiogenesis Inhibitor In: ESMO; 2008.
84. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008;14:1407-12.
85. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672-8.
86. Rini B, I, Schiller, J, Fruehauf, P, et al. Association of diastolic blood pressure ≥ 90 mmHg with overall survival in patients treated with axitinib (AG-013736). In: ASCO; 2008: J. Clin Oncol; 2008.
87. Rini B. Hypertension is a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. In: Kidney Cancer Symposium; 2009; Chicago, IL 2009.
88. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19:1659-61.
89. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-82.
90. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7:3670-84.